Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...

On Sept. 5, 2025, the U.S. Food and Drug Administration (FDA) approved Inlexzo (gemcitabine intravesical system) for adults ...

An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based ...

The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...

The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...

Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...

Urogen Pharma (($URGN)) announced an update on their ongoing clinical study. Study Overview: UroGen Pharma is conducting a Phase 3 study titled ‘A ...

Bladder cancer can be divided into different types, including non-muscle-invasive, muscle-invasive, and metastatic bladder cancer. Chemotherapy and immunotherapy are commonly used treatments, but not ...